Health
UAE company nears end of Chinese Covid-19 vaccine trial – Devdiscourse
He said G42 has distribution and manufacturing agreements with Sinopharm and hopes to provide the UAE and other regional states with the vaccine, especially tho…
A United Arab Emirates company is nearing the end of Phase III clinical trials of a Chinese COVID-19 vaccine and hopes to manufacture it next year, a representative said. The trial, which began in mid-July, is a partnership between Sinopharm’s China National Biotec Group (CNBG) and Abu Dhabi-based artificial intelligence and cloud computing company Group 42 (G42).
The vaccine uses an inactivated virus; a well-known technology which has been used against diseases such as influenza and measles. T…
-
Business18 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Noosa News14 hours agoWilliam Robinson dies aged 89
-
Business18 hours agoWhat to do with these 3 ASX 200 retail shares after strong price runs: experts
-
General13 hours agoCalls for corruption probe into completion of mayor’s Surfers Paradise Bowls Club site purchase